Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

tanespimycin 4fludarabine phosphate 4Magnetic Resonance Spectroscopy 4Cyclosporine 4Biopsy 4aldesleukin 3Vorinostat 3Specimen Handling 3Polymerase Chain Reaction 3Peripheral Blood Stem Cell Transplantation 3Irinotecan 3Gemcitabine 3Flow Cytometry 3Bortezomib 3romidepsin 2pembrolizumab 2nelarabine 2mogamulizumab 2laromustine 2entinostat 2belinostat 2alvocidib 2Psychiatric Rehabilitation 2Pharmacogenomic Testing 2Nivolumab 2Methylprednisolone 2MK 2206 2Levofloxacin 2Lenalidomide 2Interleukin-15 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Sezary Syndrome × duvelisib × Clear all
NCT04652960 2026-05-13

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

National Cancer Institute (NCI)

Phase 1 Active not recruiting
38 enrolled
Lymphoid

Mycosis Fungoides, Sezary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡